Grant: Project Grant

Despite major improvements in the treatment and prevention of cardiovascular disease, it remains the leading cause of death and hospitalization in Canada. New treatment strategies to treat cardiovascular disease are needed. Precision medicine approaches offer an attractive means to improve the efficacy of medications. In the present project, we will use genomic data analysis approaches to provide evidence that may add support for a personalized medical intervention with a drug called dalcetrapib which works by inhibiting the cholesteryl ester transfer protein (CETP). To reach those goals, we use two large genomic datasets with data available on over 520,000 patients. We will use a methodology called Mendelian randomization to assess the causal relationship between the drug and its effect on the reduction of heart disease when used in a subgroup of patients with a specific genetic profile at one gene (ADCY9). The proposed project will provide valuable evidence to support the development of a new cardiovascular medication and promote the development of precision medicine therapies.